var data={"title":"AbobotulinumtoxinA (Dysport): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">AbobotulinumtoxinA (Dysport): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/392070?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=abobotulinumtoxina-dysport-drug-information\" class=\"drug drug_general\">see &quot;AbobotulinumtoxinA (Dysport): Drug information&quot;</a> and <a href=\"topic.htm?path=abobotulinumtoxina-dysport-patient-drug-information\" class=\"drug drug_patient\">see &quot;AbobotulinumtoxinA (Dysport): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605326\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Distant spread of toxin effect:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Postmarketing reports indicate that the effects of all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life-threatening, and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including upper limb spasticity in children, and in approved indications, cases of spread of effect have been reported at doses comparable to or lower than the maximum recommended total dose.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999220\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Dysport;</li>\n      <li>Dysport (Glabellar Lines) [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51235505\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Dysport Therapeutic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49236994\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Neuromuscular Blocker Agent, Toxin</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49753669\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=abobotulinumtoxina-dysport-drug-information\" class=\"drug drug_general\">see &quot;AbobotulinumtoxinA (Dysport): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Note:</b> Potency units are specific to product and assay method utilized; do not interchange botulinum toxin products</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Lower limb spasticity:</b> <b>Note:</b> Individualize dose based on the following: Patient size, number and location of muscles involved, severity of spasticity, local muscle weakness, response to prior treatment, and/or adverse reaction history.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;2 years and Adolescents &lt;18 years: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Individual recommended dose range per muscle per limb:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Gastrocnemius: 6 to 9 units/kg/dose divided in up to 4 injections per muscle per limb; a single injection site should not exceed 0.5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Soleus: 4 to 6 units/kg/dose divided in up to 2 injections per muscle per limb; a single injection site should not exceed 0.5 mL</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total dose range per treatment session: 10 to 15 units/kg/dose for each limb up to a maximum dose of the lesser of either: Unilateral limb: 15 units/kg/dose; bilateral limbs: 30 units/kg/dose or 1,000 units/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">May repeat therapy at intervals &ge;12 weeks; in clinical studies, the majority of patients were retreated between 16 to 22 weeks; however, some patients had a longer duration of response.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cervical dystonia:</b> IM: Initial: 500 units divided among affected muscles in toxin-na&iuml;ve or toxin-experienced patients. May retreat at intervals of &ge;12 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustments:</i> Adjust dosage in 250-unit increments; do not administer at intervals &lt;12 weeks; dosage range used in studies: 250 to 1,000 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Glabellar lines: </b>Adults &lt;65 years: IM: Inject 10 units into each of 5 sites (2 injections in each corrugator muscle and 1 injection in the procerus muscle) for a total dose of 50 units; do not administer at intervals &lt;3 months; efficacy has been demonstrated with up to 4 repeated administrations</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Upper limb spasticity:</b> IM: Individualize dose based on patient size, number, and location of muscle involvement; severity of spasticity; local muscle weakness; response to prior treatment; and/or adverse reaction history. May repeat therapy at intervals &ge;12 weeks; in clinical studies, the majority of patients were retreated between 12 to 16 weeks; however, some patients had a longer duration of response (eg, 20 weeks). Total doses of 500 and 1,000 units divided among selected muscles were used in clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brachialis: 200 to 400 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Brachioradialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Biceps brachii: 200 to 400 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor carpi radialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor carpi ulnaris: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor digitorum profundus: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Flexor digitorum superficialis: 100 to 200 units (1 to 2 injections per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pronator teres: 100 to 200 units (1 injection per muscle)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as abobotulinumtoxinA is not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely as abobotulinumtoxinA is not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605595\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intramuscular: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dysport: 300 units (1 ea); 500 units (1 ea) [contains albumin human, milk protein]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dysport (Glabellar Lines): 300 units (1 ea [DSC]) [contains albumin human, milk protein]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605328\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605327\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125274s109lbl.pdf#page=30&amp;token=xQJV5Tov+soBfbZnrE0L38u2/igp3JjgxyR9Bu/4QvcdF608pofddFbTWmFLYWYyiqNy+X/x79cxgTmnIdmfHccE4s9PBmBRpXViNOwL48YyZhjjtwr7SVWrM2vN8kpl&amp;TOPIC_ID=112663\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125274s109lbl.pdf#page=30</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49236998\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Lower limb spasticity: IM: Use an appropriately sized sterile syringe (eg, 3 mL) and needle to administer intramuscularly. Although actual location of the injection sites can be determined by palpation, the use of an injection guiding technique (eg, electromyography or electrical stimulation) is recommended to target the injection sites. Do not administer &gt;0.5 mL in any single injection site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cervical dystonia: Use an appropriately sized gauge needle to administer intramuscularly. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia. Simultaneous EMG-guided application may be helpful in locating active muscle not identified by physical examination alone.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Glabellar lines: Use a 30-gauge needle to administer intramuscularly. Apply pressure on the superior medial orbital rim, and inject into each of 5 sites (2 injections in each corrugator muscle and 1 in the procerus muscle). Ensure injected volume/dose is accurate and where feasible keep to a minimum. Avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Medial corrugator injections should be at least 1 cm above the bony supraorbital ridge. Do not inject toxin closer than 1 cm above the central eyebrow.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Upper limb spasticity: Use an appropriately sized sterile needle to administer intramuscularly. Although actual location of the injection sites can be determined by palpation, the use of injection guiding technique (eg, electromyography, electrical stimulation) is recommended to target the injection sites. No more than 1 mL should generally be administered at any single injection site.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605470\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store undiluted vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. After reconstitution, store vials in original container under refrigeration, protect from light, and use within 24 hours (does not contain preservative); single-use vials. Do not freeze after reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49236995\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of lower limb spasticity (FDA approved in pediatric patients 2 to 17 years); treatment of cervical dystonia (FDA approved in adults); temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and procerus muscle activity (FDA approved in adults &lt;65 years); treatment of upper limb spasticity (to decrease the severity of increased muscle tone in elbow flexors, wrist flexors, and finger flexors) (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7999218\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Botulinum products are not interchangeable; potency differences may exist between the products.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605447\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical dystonia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased heart rate</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Dizziness, facial paresis, fatigue, headache, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Dysphagia, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development (binding or neutralizing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Discomfort at injection site, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Amyotrophy, musculoskeletal pain, myasthenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Eye disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (onset: ~1 week; duration: ~3 weeks)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Glabellar lines:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Contact dermatitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Discomfort at injection site, injection site reaction, pain at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blepharoptosis, eyelid edema</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis, cough, nasopharyngitis, pharyngolaryngeal pain, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Upper limb spasticity:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormal gait, convulsions, depression, dizziness, falling, fatigue, feeling of heaviness, headache, hypertonia, hypoesthesia, myasthenia, seizure (partial)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Increased serum triglycerides</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation, diarrhea, dysphagia, nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection, influenza</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain, limb pain, musculoskeletal pain, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, nasopharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Accidental injury</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Lower limb spasticity: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (adults), peripheral edema (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Depression (adults), epilepsy, falling (more frequesnt in patients &ge;65 years of age), fatigue (adults), headache (adults), insomnia (adults), myasthenia, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Constipation (adults), dysphagia (adults), nausea (children &amp; adolescents), viral gastroenteritis (children &amp; adolescents), vomiting (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bruise (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Influenza (children &amp; adolescents), varicella (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Arthralgia (adults), back pain (adults), bone fracture (adults, wrist), limb pain, weakness (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Otic infection (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Bronchitis (children &amp; adolescents), cough (children &amp; adolescents), flu-like symptoms (adults), nasopharyngitis (children &amp; adolescents), oropharyngeal pain (children &amp; adolescents), pharyngitis (children &amp; adolescents), rhinitis (children &amp; adolescents), upper respiratory tract infection (more common in children &amp; adolescents), viral respiratory tract infection (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (children &amp; adolescents)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Any indication: </b>Rare but important or life-threatening: Anaphylaxis, blurred vision, burning sensation, connective tissue disease (excessive granulation tissue), diplopia, dysarthria, dysphagia, erythema, facial paresis, hypersensitivity reaction, hypoesthesia, photophobia, urinary incontinence, xerophthalmia, vertigo</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605334\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity (eg, anaphylaxis) to botulinum toxin or any component of the formulation, including cow milk protein; infection at the proposed injection site(s)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605335\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis/hypersensitivity reactions: Hypersensitivity and anaphylactic reactions may occur rarely; immediate treatment (including epinephrine 1 mg/mL) should be available.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: Higher doses or more frequent administration may result in neutralizing antibody formation and loss of efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: Rarely, arrhythmia and myocardial infarction have been reported with use of onabotulinumtoxinA (another botulinum toxin formulation), sometimes in patients with preexisting cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dysphagia: Common when used for cervical dystonia and may persist for several weeks after administration. In severe cases, patients may require alternative feeding methods (eg, feeding tube). Risk factors include smaller neck muscle mass, bilateral injections into the sternocleidomastoid muscle, or injections into the levator scapulae. Risk of aspiration resulting from severe dysphagia is increased in patients when swallowing is already compromised. Limiting the dose injected into the sternocleidomastoid muscle may reduce the occurrence of dysphagia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic toxicity: <b>[US Boxed Warning]: Distant spread of botulinum toxin beyond the site of injection has been reported; dysphagia and breathing difficulties have occurred and may be life threatening; other symptoms reported include asthenia, blurred vision, diplopia, dysarthria, dysphonia, generalized muscle weakness, ptosis, and urinary incontinence which may develop within hours or weeks following injection.</b> Risk likely greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions. Systemic effects have occurred following use in approved and unapproved uses including lower than the maximum recommended total dose. Immediate medical attention required if respiratory, speech, or swallowing difficulties appear.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neuromuscular disease: Use with caution in patients with neuromuscular diseases (eg, myasthenia gravis, Eaton-Lambert syndrome) and neuropathic disorders (eg, amyotrophic lateral sclerosis).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular diseases: Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration when treating blepharospasm. Retrobulbar hemorrhages may occur from needle penetration into orbit when treating strabismus; spatial disorientation, double vision, or past-pointing may occur if one or more extraocular muscles are paralyzed. Covering the affected eye may help. Careful testing of corneal sensation, avoidance of lower lid injections, and treatment of epithelial defects are necessary. Use caution in patients with angle closure glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory disease: Use extreme caution in patients with preexisting respiratory disease; treatment of cervical dystonia using botulinum toxin may weaken accessory muscles that are necessary for these patients to maintain adequate ventilation. Serious breathing difficulties, including respiratory failure, have been reported. Risk of aspiration resulting from severe dysphagia is increased in patients with decreased respiratory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Product contains albumin and may carry a remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose: Product may contain lactose; do not administer to patients allergic to cow's milk protein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Product interchangeability: Botulinum products (abobotulinumtoxinA, onabotulinumtoxinA, rimabotulinumtoxinB) are not interchangeable; potency units are specific to each preparation and cannot be compared or converted to any other botulinum product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Temporary reduction in glabellar lines: Efficacy was not observed in older adults (&ge;65 years of age) and an increased frequency of ocular adverse events was reported in older adults compared to younger adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Lower limb spasticity: Safety and effectiveness of injection into proximal muscles of the lower limb have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic therapy: Long-term effects of chronic therapy unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site: Use with caution if there is inflammation or excessive weakness or atrophy at the proposed injection site(s); use is contraindicated if infection is present.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperhidrosis: Safety in the treatment of hyperhidrosis has not been established. The possibility of an immune reaction resulting from an intradermal injection is unknown.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Temporary reduction in glabellar lines: Appropriate use: Do not use more frequently than every 3 months. Patients with marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or the inability to substantially lessen glabellar lines by physically spreading them apart were excluded from clinical trials. Use with caution in patients with surgical alterations to the facial anatomy. Reduced blinking from injection of the orbicularis muscle can lead to corneal exposure and ulceration. Spatial disorientation, double vision, or past pointing may occur if one or more extraocular muscles are paralyzed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298630\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9349502\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=112663&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: May enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the anticholinergic effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents: AbobotulinumtoxinA may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: May enhance the adverse neuromuscular effect of AbobotulinumtoxinA.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: AbobotulinumtoxinA may enhance the adverse neuromuscular effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605331\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49753672\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor patients closely for signs/symptoms of systemic toxic effects (possibly occurring 1 day to several weeks after treatment) and therapeutic endpoints based on use.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Lower limb spasticity: Modified Ashworth Scale; overall treatment goals include: Improved gait and balance, facilitation of patient care, increased comfort with therapy, improved tolerance of bracing, and prevention of musculoskeletal complications</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605472\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">AbobotulinumtoxinA (previously known as botulinum toxin type A) is a neurotoxin produced by <i>Clostridium botulinum</i>, spore-forming anaerobic bacillus, which appears to affect only the presynaptic membrane of the neuromuscular junction in humans, where it prevents calcium-dependent release of acetylcholine and produces a state of denervation. Muscle inactivation persists until new fibrils grow from the nerve and form junction plates on new areas of the muscle-cell walls.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9605474\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Peak effect: Cervical dystonia: 2 to 4 weeks; Upper limb spasticity: 1 week </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Cervical dystonia, glabellar lines: &ge;4 months; Lower limb spasticity: &ge;5 &frac12; months; Upper limb spasticity: &ge;5 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Not expected to be present in peripheral blood at recommended doses following intramuscular (IM) injection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322606\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Dysport Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 unit (1): $589.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (1): $982.20</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26343897\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Dysport (AE, AR, AT, AU, BB, BE, BG, BR, CH, CO, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HK, HU, IE, IL, IT, JO, KR, LB, LT, LU, LV, MT, MX, MY, NL, NO, NZ, PH, PL, PT, QA, RO, RU, SE, SG, SI, SK, TH, TR, VN, ZA);</li>\n      <li>Nabota (PH)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Brisinda G, Albanese A, Cadeddu F, et al. Botulinum neurotoxin to treat chronic anal fissure: results of a randomized &quot;Botox vs. Dysport&quot; controlled trial. <i>Aliment Pharmacol Ther</i>. 2004;19(6):695-701.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/15023172/pubmed\" target=\"_blank\" id=\"15023172\">15023172</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dysport (abobotulinumtoxinA) [prescribing information]. Basking Ridge, NJ: Ipsen Biopharmaceuticals; July 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hennings JM, Krause E, B&ouml;tzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(5):1167-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/17936461/pubmed\" target=\"_blank\" id=\"17936461\">17936461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rapaport A, Sadeh M, Stein D, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. <i>Mov Disord</i>. 2000;15(2):352-355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/10752596/pubmed\" target=\"_blank\" id=\"10752596\">10752596</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reddihough D, Erasmus CE, Johnson H, McKellar GM, Jongerius PH; Cerebral Palsy Institute. Botulinum toxin assessment, intervention and aftercare for paediatric and adult drooling: international consensus statement. <i>Eur J Neurol</i>. 2010;17 (suppl 2):109-121.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/20633182/pubmed\" target=\"_blank\" id=\"20633182\">20633182</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruben ST, Lee JP, O'Neil D, Dunlop I, Elston JS. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. <i>Ophthalmology</i>. 1994;101(4):783-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/8152776/pubmed\" target=\"_blank\" id=\"8152776\">8152776</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simpson DM, Hallett M, Ashman EJ. et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. <i>Neurology</i>. 2016;86(19):1818-1826. doi: 10.1212/WNL.0000000000002560.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/27164716/pubmed\" target=\"_blank\" id=\"27164716\">27164716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siproudhis L, S&eacute;bille V, Pigot F, H&eacute;mery P, Juguet F, Bellissant E. Lack of efficacy of botulinum toxin in chronic anal fissure. <i>Aliment Pharmacol Ther</i>. 2003;18(5):515-524.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/12950424/pubmed\" target=\"_blank\" id=\"12950424\">12950424</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Slotema CW, van Harten PN, Bruggeman R, Hoek HW. Botulinum toxin in the treatment of orofacial tardive dyskinesia: a single blind study. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(2):507-509.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/18022743/pubmed\" target=\"_blank\" id=\"18022743\">18022743</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. <i>Otolaryngol Head Neck Surg</i>. 2013;148(2):191-196. doi: 10.1177/0194599812465059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/23112272/pubmed\" target=\"_blank\" id=\"23112272\">23112272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yiannakopoulou E. Botulinum toxin and anal fissure: efficacy and safety systematic review. <i>Int J Colorectal Dis</i>. 2012;27(1):1-9. doi: 10.1007/s00384-011-1286-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/abobotulinumtoxina-dysport-pediatric-drug-information/abstract-text/21822595/pubmed\" target=\"_blank\" id=\"21822595\">21822595</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 112663 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F9605326\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F7999220\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F51235505\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F49236994\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F49753669\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F9605595\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F9605328\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F9605327\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F49236998\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F9605470\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F49236995\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7999218\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F9605447\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F9605334\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F9605335\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298630\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F9349502\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F9605331\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49753672\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F9605472\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F9605474\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322606\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F26343897\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/112663|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=abobotulinumtoxina-dysport-drug-information\" class=\"drug drug_general\">AbobotulinumtoxinA (Dysport): Drug information</a></li><li><a href=\"topic.htm?path=abobotulinumtoxina-dysport-patient-drug-information\" class=\"drug drug_patient\">AbobotulinumtoxinA (Dysport): Patient drug information</a></li></ul></div></div>","javascript":null}